<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment started on day 1 (visit 1) and lasted for 7 days until day 8 (visit 3). At day 4 (visit 2) an early clinical assessment was performed. Follow-up was 30 days after the last treatment date (day 38; visit 4) to evaluate sustained outcome as a secondary endpoint [
 <xref rid="B23" ref-type="bibr">23</xref>]. The only concomitant symptomatic treatment permitted was paracetamol, which was documented.
</p>
